Home - Products - Cell Cycle/DNA Damage - Integrin - Natalizumab

Natalizumab

CAS No. 189261-10-7

Natalizumab( —— )

Catalog No. M23864 CAS No. 189261-10-7

Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	218	In Stock
5MG	392	In Stock
10MG	629	In Stock
25MG	938	In Stock
50MG	1237	In Stock
100MG	1665	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Natalizumab
Note

Research use only, not for human use.
Brief Description

Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
Description

Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Cell Cycle/DNA Damage
Target

Integrin
Recptor

α4β1 integrin
Research Area

——
Indication

——

Chemical Information

CAS Number

189261-10-7
Formula Weight

——
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1.Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3(2):259-68.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

OSU-T315

A novel potent, orally active ILK (integrin-linked kinase) inhibitor with IC50 of 0.6 uM.
GPRP

GPRP (Gly-Pro-Arg-Pro) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein IIb/IIIa complex (glycoprotein IIb/IIIa receptor).
TBC3486

A potent, selective, non-peptidic integrin α4β1 (VLA-4) antagonist with IC50 of 9 nM.

Sign In Join Free